Research and Development Programs Sample Clauses

Research and Development Programs. Subject to Section 2.1 and in reliance upon the representations, warranties and covenants under Article 8 of this Agreement, Newco hereby agrees to assume BD's obligations under the Research Program and the Development Program pursuant to the BD/MPI Collaboration Agreement, including without limitation, undertaking those obligations of BD set out in Sections 2.7(c) and 2.10 of the BD/MPI Collaboration Agreement with respect to the Research Program and Development Program, respectively.
Sample 1
AutoNDA by SimpleDocs
Research and Development Programs. (a) Within twenty Business Days after the Effective Date and at least twenty Business Days prior to each anniversary of the Effective Date during the Term, the Foundation must prepare and document, in consultation with and to the satisfaction of the person nominated by GTG in accordance with clause 0, a Research and Development Program for the immediately succeeding Year. (b) The Foundation and GTG must act reasonably and in good faith and must not unreasonably delay in reaching agreement on the content of (including Research Projects forming part of) each Research and Development Program. If the parties are unable to agree on all Research Projects on which the Funds should be expended during the relevant Year, GTG must pay all of the Funds to the Foundation in accordance with this agreement but the Foundation must not (except with the prior written consent of GTG) expend the Funds to the extent there is no approved Research Project for the expenditure of the Funds. (c) Each Research and Development Program must: (i) detail each Research Project to be carried out during the relevant Year, including provision of a Research Project Plan and details of the Milestones and intended objectives for each Research Project; (ii) specify a strategy for the carrying out of those Research Projects; (iii) allocate the Funds for the relevant Year (and any non-expended Funds from any previous Years) as between the Research Projects detailed in the Research and Development Program; (iv) detail any research incentives to be offered (whether from the Funds or some other source) to Foundation Personnel during the relevant Year, which may include: A. travel grants; B. scientific retreats; C. enrolment at University of Western Australia in the form of a tax free scholarship; D. enrolment in special technical/business courses; E. cross visits/secondments between GTG and the Foundation; and F. visits/tours of laboratories operated by or on behalf of or affiliated with either party. (d) The Foundation must during the Year to which a Research and Development Program relates give effect to that Research and Development Program, including carrying out the Research Projects detailed in or contemplated by the Research and Development Program in accordance with the relevant Research Project Plans.
Sample 1
Research and Development Programs. The Company's portfolio of stem cell technology results from the Company's exclusive licensing of neural stem/progenitor cell technology and other technologies applicable to the pancreas and liver, the Company's own research and development efforts to date, and the acquisition of StemCells, Inc. (now renamed StemCells California, Inc.) in 1997. The Company, through its subsidiary, StemCells California, Inc., has been advancing its program directed to the discovery, isolation and culturing of various stem cells from the human body. The Company believes that therapies using stem cells represent a fundamentally new approach to the treatment of diseases caused by lost or damaged tissue. The Company has assembled an experienced team of scientists and scientific advisors to consult with and advise the Company's scientists on their continuing research and development of stem/progenitor cells. This team includes, among others, Xxxxxx X. Xxxxxxxx, M.D., of Stanford University, Xxxx
Sample 1
Research and Development Programs. 6 3.5.1 Services of Other A&M Employees .................... 6 3.5.2 Cost ............................................... 7 3.6 Research Data and Information ............................... 7 3.6.1 Access to A&M Information .......................... 7 3.6.2 Ownership of Intellectual Property ................. 7 3.6.3 Newly Created or Discovered Intellectual Property .. 7 3.6.4
Sample 1
Research and Development Programs. The JSC may from time to time establish one or more Research Programs or Development Programs directed to the Treatment of SARS-CoV-2 Indications by Collaboration Products in the Field, each by putting in place a Plan and Budget for the particular program as described in Section 1.68. Each Party shall use Commercially Reasonable Efforts to perform and complete the activities allocated to such Party under each such Plan and Budget in a collaborative manner and within the timeframes set forth therein. The Parties anticipate that the Development Lead will be primarily responsible for all activities under a Development Plan and Budget, but in all cases appropriately leveraging the personnel, infrastructure and expertise of (and informing) the other Party. Notwithstanding the foregoing, in the case of the Ad5 Vaccine Product, NantKwest will be primarily responsible for Manufacturing activities outlined in the Plans.
Sample 1
Research and Development Programs 
Sample 1Sample 2Sample 3See All (5)

Related to Research and Development Programs

  • Research and Development (i) Advice and assistance in relation to research and development of Party B; (ii) Advice and assistance in strategic planning; and

  • Professional Development Program (a) The parties agree to continue a Professional Development Program for the maintenance and development of the faculty members' professional competence and effectiveness. It is agreed that maintenance of currency of subject knowledge, the improvement of performance of faculty duties, and the maintenance and improvement of professional competence, including instructional skills, are the primary professional development activities of faculty members. (b) Information collected as part of this program shall be the sole property of the faculty member. This information or any judgments arising from this program shall not be used to determine non-renewal or termination of a faculty member's contract, suspension or dismissal of a faculty member, denial of advancement on the salary scale, nor affect any other administrative decisions pertaining to the promotion or employment status of the faculty member. (c) A joint advisory committee consisting of three regular faculty members who shall be elected by and are P.D. Committee Chairpersons and three administrators shall make recommendations for the operation, financing and management of the Professional Development Program.

  • Curriculum Development This includes the analysis and coordination of textual materials; constant review of current literature in the field, some of which are selected for the college library collection, the preparation of selective, descriptive materials such as outlines and syllabi; conferring with other faculty and administration on curricular problems; and, the attendance and participation in inter and intra-college conferences and advisory committees.

  • Training and Development 3.1 Authorities will develop local 'Workforce Development Plans (see Part 4.8),' closely linked to their service delivery plans, which will provide the focus for the establishment of training and development priorities. Training and development should be designed to meet the corporate and service needs of authorities both current and in the future, taking into account the individual needs of employees. Local schemes on training and development should enable authorities to attain their strategic objectives through development of their employees. Training and development provisions should be shaped to local requirements and take account of the full range of learning methods. Such an approach should enable access to learning for all employees. The needs of part time employees and shift workers need particular consideration. 3.2 Employees attending or undertaking required training are entitled to payment of normal earnings; all prescribed fees and other relevant expenses arising. Employees are also entitled to paid leave for the purpose of sitting for required examinations. When attending training courses outside contracted daily hours, part-time employees should be paid on the same basis as full- time employees. (Assistance for other forms of learning, for example that directed at individual development, will be locally determined). Some training can be very expensive and authorities may require repayment of all or part of the costs incurred should an employee leave the authority before a reasonable time period has expired. The authority's policy in this regard should be made explicit. 3.3 Objectives for training and development programmes should include the following: • To enable Councils to attain their strategic objectives via investment in their employees. • To promote equity of access to learning. • To encourage employees to develop their skills and level of responsibility to the maximum of their individual potential. • To widen and modernise the skills profile of employees to maximise their versatility, employability and so, job security. • To enable employees to raise productivity, quality and customer service in pursuit of sustainable improvement 3.4 Authorities should establish local partnership arrangements, to include recognised trade unions, to develop their local workforce development plans. 3.5 The NJC endorses partnership provision such as the "Return to Learn" scheme. Authorities and the recognised trade unions shall encourage and support employees taking on the statutory Union Learning Representative (ULR) role. This will include agreeing facilities and paid release in accordance with statutory provisions. ULRs should be enabled to play a full part in promoting and implementing local training and development programmes.

  • Program Development NWESD agrees that priority in the development of new applications services by XXXXX shall be in accordance with the expressed direction of the XXXXX Board of Directors operating under their bylaws.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Professional Development Plan Professional Development Plan (PDP) refers to plans developed by faculty members addressing the criteria contained in Article 22 and Appendix G.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!